Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors
Alimentary Pharmacology & Therapeutics · 2026-11-19
DOI: 10.1111/apt.71083 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-11-19. Written by Corey A. Siegel and 5 co-authors. 23 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Understanding long‐term differences in real‐world treatment patterns in patients with ulcerative colitis treated with advanced therapies may provide insight into treatment effectiveness and patient preference.
Aims
To evaluate real‐world treatment patterns over 24 months including treatment switching and adherence (overall and advanced‐therapy–experienced populations), in patients with ulcerative colitis initiating upadacitinib compared with those initiating adalimumab or infliximab.
Methods
This was a retrospective, cohort study using administrative claims data from the Merative MarketScan US commercial and Medicare databases (January 2022–October 2025). Adults with ulcerative colitis initiating treatment with upadacitinib, adalimumab, or infliximab were included and evaluated for differences in switching and adherence over 24 months after the index date. Multivariable regression analyses were conducted to control for confounders.
Results
946 patients with ulcerative colitis were included; upadacitinib ( n = 164; [17.3%]), adalimumab ( n = 475; [50.2%]) and infliximab ( n = 307 [32.5%]). At 24 months, upadacitinib had the lowest rate of switching to a new advanced therapy (20.1%) versus infliximab (49.2%) or adalimumab (49.7%); adjusted odds of switching were significantly higher with other therapies compared with upadacitinib (all p < 0.001). Upadacitinib had the highest adherence at 24 months (68.3%) versus adalimumab (40.0%) or infliximab (42.3%). Similar trends were observed in the advanced‐therapy–experienced population and after adjusting for differences in baseline characteristics.
Conclusions
In this real‐world claims‐based analysis of patients with ulcerative colitis, treatment with upadacitinib was associated with the lowest switch rate and highest adherence rate when compared with adalimumab or infliximab.
Cite
APA
Siegel, C. A., Ungaro, R. C., Kim, J. R., Shukla, N., Morisset, P., & Seidelin, J. (2026). Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71083
Vancouver
Siegel CA, Ungaro RC, Kim JR, Shukla N, Morisset P, Seidelin J. Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71083
BibTeX
@article{Siegel2026,
author = {Siegel, Corey A. and Ungaro, Ryan C. and Kim, Jae Rok and Shukla, Nidhi and Morisset, Pierre and Seidelin, Jakob},
title = {Long‐Term Real‐World Switch Rates and Adherence Among Patients With Ulcerative Colitis Treated With Upadacitinib or Tumour Necrosis Factor Inhibitors},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71083}
}
EUVIMED